Executive Director, Global Program Lead, Oncology (Pumitamig)

Executive Director, Global Program Lead, Oncology (Pumitamig)

Princeton - NJ - US

Working with Us Challenging. Meaningful. Life-changing. Those aren't words that are usually associated with a job. But working at Bristol Myers Squibb is anything but usual. Here, uniquely interesting work happens every day, in every department. From optimizing a production line to the latest breakthroughs in cell therapy, this is work that transforms the lives of patients, and the careers of those who do it. You'll get the chance to grow and thrive through opportunities uncommon in scale and scope, alongside high-achieving teams. Take your career farther than you thought possible.

Bristol Myers Squibb recognizes the importance of balance and flexibility in our work environment. We offer a wide variety of competitive benefits, services and programs that provide our employees with the resources to pursue their goals, both at work and in their personal lives.

Position Summary

BMS is hiring an Executive Director, Global Program Leader, Pumitamig. This individual will report to the Vice President, GPL Pumitamig, and will be responsible for leading a portion of the Pumitamig development book of work. Pumitamig is a PD-L1xVEGFF bispecific antibody being developed in a range of solid tumors in collaboration with our external partner BioNTech.

Global Program Leads within the HOCT (Hematology, Oncology & Cell Therapy) Global Program Leadership organization are strategic-thinking, problem-solving, and action oriented scientific leaders who bring drug development and commercialization insights to drive a sustainable pipeline of innovative medicines. GPLs serve as the "point of accountability" for their assets and are respected, matrix leaders, overseeing multi-disciplinary teams. They foster a high performing, highly collaborative, truth-seeking team environment aimed at developing and implementing compelling, integrated asset strategies to achieve ambitious near- and long-term portfolio objectives. Each leader is accountable to therapeutic area, R&D, commercial and Company Leadership for: (i) creating a vision and defining the strategy and integrated development plan for each asset within their portfolio, (ii) developing a set of objective criteria against which each asset advancing through the pipeline will be evaluated to enable robust debate and rapid, data-driven decision making; and (iii) ensuring that only high quality and differentiated assets enter the market.

Key Responsibilities

Strategy and Execution

• Uses an understanding of disease biology, the drug development process (particularly cross-functional connectivity), and relevant late-stage challenges (e.g., trends in disease area therapeutic advances, and evolving regulatory, patient advocacy and market access environments) to create a vision for each asset, then design and execute effective development programs in support of the overall R&D portfolio goals.
• Effectively engages cross company expertise and utilizes advisory groups and governance bodies to define, revise and champion asset development strategies and implementation plans.
• Continually analyzes progress, engages in critical thinking, and asserts strong problem-solving toward delivering key data and interpretation essential for robust debate and rapid, data-driven decision making on assigned projects.
• Delivers high quality assets to commercial which have the potential for a competitive profile to address the unmet medical needs of patients and to provide favorable shareholder return.
• Ensures the process and output of the team meets established program standards (per PD&C Process expectations, within budget, on schedule, compliant, etc.), while also looking for opportunities to streamline development and enable continuous improvements without compromising quality.
• Engages senior leaders and functional area stakeholders to ensure alignment of program strategy and operational plans with functional area capabilities, and clearly communicates program risks, implications of changes in the competitive landscape and progress toward key milestones.
• Actively provides input to and drives portfolio level strategy for both internal and external opportunities.
• Participates in regulatory filings (NDA, BLA filings) as well as develops strategy for orphan drug designation.
• Engages with Health Authorities and/or Advisory Committees in the design of clinical trials and endpoints.
• Leads team to develop program strategy and clinical program, commercialization strategy plans, business case development, and understands how access, pricing and reimbursement needs for supporting value proposition will inform trial design.
• Builds and maintains collaborative relationships with external stakeholders (Opinion Leaders, Strategic Alliance Partners, Patient Advocacy Leaders, Health Authorities) and appropriately incorporates insights and advice to maximize program impact.
• Understands clinical trial operational complexities from study start up through enrollment, quality assurance, and study readout.
• Has an active role in analysis and/or interpretation of clinical data and translation into scientific communication strategy, including publications, and commercial strategy.
• Understands and reflects the impact of VAP inputs (Early Access Review and DEX recommendations, commercial opportunity assessment, TOP / TPP requirements, and value drivers as inputs in clinical trial design.
• Actively supports Investor Relations and Public Affairs in managing external BMS communications.
• Integrates commercialization inputs and deliverables to design the late program strategy that enables approval of a meaningfully differentiated asset with potential to maximize asset value.
• Understands necessary commercial inputs needed to inform the end-to-end development process leading to regulatory approval and successful commercialization.
• Integrates market inputs (e.g., TPP, DEX/VAP, CI insights) into the integrated development plan, including clinical plans and labeling strategy; Appreciates translation of clinical data into claims and considerations for label development.
• Understands and contributes to development of forecasts and investment scenarios, how to assess risk and conduct valuations, and implications for decision-making.
• Contributes to the development of brand hallmarks and brand strategy (generic name, brand name, logo, brand colors, positioning, messaging, campaign, segmentation, promotional strategy) understanding the relationship to clinical trial design.
• In partnership with Medical Affairs, supports development of KOL plans and engagements, and leverages KOL input in context of development programs and communicating evidence.
• Supports commercial needs and recommendations to guide CMC and GPS on trade packaging and commercial product.

Leadership and Matrix Alignment

• Inclusively Collaborates Across the BMS Matrix with an Enterprise Mindset: Effectively collaborates with matrix functions by building trust and driving toward the collective success of the program
• Demonstrates Enterprise Mindset Problem-Solving and Decision Making: Gathers diverse perspectives assess alternate resolutions and makes thoughtful, informed Enterprise decisions
• Develops and Leads a High Performing Matrix Team: Builds, leads and inspires high performing cross functional matrix team through a unified program strategy on behalf of our patients
• Holds Oneself and Others Accountable: Takes initiative to address challenges, removes barriers, holds others accountable for the collective success of the program outcomes and team collaboration
• Demonstrates Character: Leads with integrity & the values of self-awareness & humility and seeks feedback

Qualifications & Experience

• MD, PhD, DVM, PharmD, MBA or equivalent advanced degree of relevance, with experience in the drug development process.
• 10+ years of experience in the drug development process and leadership experience in academic or industry setting, including education where applicable.
• Expertise in the drug development process with in-depth know-how and experience in matrix team leadership, relevant regulatory expectations, and overall drug development and commercialization.
• Successful track record of leading through influence and working across complex, global organizational matrix.
• Significant experience in oncology, specifically lung preferred, with demonstrated understanding of the role of basic biology, pharmaceutical optimization, translational medicine, and clinical pharmacology, including exposure-response relationships and dose selection.
• Strong understanding of relevant regulatory health authority expectations and regulations for drug development and impact on commercialization.
• Working knowledge of all functional areas of exploratory development, including chemistry/biochemistry, biology, toxicology, CMC, translational medicine, early clinical development, etc.
• Demonstrated scientific acumen and mechanistic understanding of pharmacology and disease biology.
• Ability to create a clear purpose, global vision, strategies and key priorities for competing successfully in the evolving pharmaceutical and health care industry.
• Demonstrated ability to lead cross-functional team to execute Development Plans which have global perspective and focus on product differentiation, including opportunities for data driven acceleration.
• Demonstrated ability to objectively assess complex but relatively sparse data sets, make informed decisions and take action in the face of uncertainty.
• Demonstrated ability to present complex programs to senior leaders and influence decision making.
• Experience in successfully managing and leading high performing, cross-functional matrix teams or complex multi-functional organizations.
• Demonstrated ability to coach and mentor others to enhance performance and/or facilitate career progression.
• Ability to effectively and seamlessly multi-task, and prioritize across multiple development assets, with complex strategies and accelerated development timelines.
• Demon